PLAINSBORO, N.J., May 1, 2025 /PRNewswire/ -- Today, Novo Nordisk announced that CVS ... preferred GLP-1 medicine on its largest commercial template formularies. This change will be effective ...

will soon be the preferred GLP-1 medicine on its largest commercial template formularies. This change will be effective July 1, 2025. Independent of this formulary decision, Novo Nordisk will ...

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template formularies, Novo said Thursday. CVS Caremark, which forms the ...

Meanwhile, Novo touted its recent efforts to boost Wegovy access, including through collaborations with telehealth companies and a prime position on CVS's national template formulary. Looking ...

The US FDA has accepted Novo Nordisk’s new drug application (NDA) submission for the 25 mg oral formulation of Wegovy ...

The e-methanol plant, built by European Energy & Mitsui, will supply companies including Maersk, LEGO & Novo Nordisk with ...

And last week, it was announced that CBS chose Wegovy to be the only GLP-1 medicine covered for obesity on its national template formulary as of July 1, 2025. While Novo Nordisk is committed to ...

The Department of Agriculture has officially declared this province as the Ginger Capital of the Philippines.Gov. Jose V.

The Indianapolis-based drugmaker also reaffirmed its 2025 revenue guidance but noted that the calculation was based on existing tariff and trade policies.

treatment on its template formularies starting 1 July. CVS’s decision is expected to expand access to Novo’s weight-loss therapy, whilst limiting coverage for Lilly’s Zepbound, potentially ...